Equity Profile

ELVN

Enliven Therapeutics, Inc.

Health CarePharmaceuticals$4.3B

Aug12Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Enliven Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for serious health conditions....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

-0.48

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams or partnerships will be critical for investor confidence.

Wall Street expectations, options signals, track record, and call prep available with Pro.

ELVN Q2-2026 Earnings Preview

Context

Company Snapshot

Enliven Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for serious health conditions. Operating in the health care sector, it plays a crucial role in addressing unmet medical needs, which is increasingly important as the demand for effective treatments continues to grow.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.56%

Avg Stock Reaction

-0.48%

Last Quarter Recap

In Q1-2026, Enliven reported an EPS of -0.38, which was better than the expected -0.44, resulting in a slight stock decline of 2.21% the following day. The company continues to navigate its development pipeline amidst ongoing challenges.

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect a loss of $0.48 per share this quarter, with no revenue anticipated. Investors will be closely watching for any signs of progress in the company's drug development efforts.

Bull Case

If Enliven can exceed EPS expectations and provide positive updates on its pipeline, it could boost investor confidence and lead to a significant stock rally.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides no clear path to future revenue, it may face further stock declines.

Key Metrics to Watch

EPS

-0.48

Earnings per share (EPS) is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams or partnerships will be critical for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of -0.48?

A better-than-expected EPS could signal operational improvements and boost investor sentiment.

What updates can management provide on the drug development pipeline?

Investors are keen to understand the potential for future revenue generation from ongoing projects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street is overly pessimistic about Enliven's ability to manage costs effectively, given its recent operational improvements that may not be fully reflected in the consensus EPS estimate.

Supporting Evidence

The company has a history of beating EPS expectations, with a 75% beat rate over the last eight quarters.

Options pricing indicates a significant expected move, suggesting that investors are bracing for potential positive news.

Recent operational efficiencies may not be fully appreciated by analysts, leading to an underestimation of potential EPS improvements.

Key Risk

If the EPS comes in better than -0.44, it could challenge the current negative sentiment and lead to a reassessment of the company's outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it reflects the company's ability to manage costs and progress its drug development amidst a challenging environment.

Bull Confirmed If

An EPS of -0.44 or better, along with positive commentary on the drug pipeline, would confirm the bull case.

Bear Confirmed If

An EPS worse than -0.52, coupled with no updates on revenue-generating projects, would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±39.04%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±39.0% while ELVN has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

45.5%

Calls (3K)P/C Ratio: 0.99Puts (39K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Enliven beats EPS expectations, history suggests the stock could see a modest increase, confirming that operational improvements are underway.

In-Line / Cautious

If results are in line with expectations, the stock may remain stable, but cautious commentary could lead to a slight decline.

Miss

If the company misses EPS estimates, history suggests a potential decline of around 1.62%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the drug development pipeline and timelines for upcoming trials.
2Details on cost management strategies and their impact on future earnings.
3Insights into potential partnerships or collaborations that could drive revenue.
4Management's outlook on market conditions and how they affect the business.
5Any commentary on regulatory approvals or setbacks that could impact product launches.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Enliven Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for serious health conditions....

Key Metrics to Watch

EPS

Earnings per share (EPS) is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

-0.48

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams or partnerships will be critical for investor confidence.

Wall Street expectations, options signals, track record, and call prep available with Pro.

ELVN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.56%

Avg Stock Reaction

-0.48%

Last Quarter Recap

Management Promises & Guidance

Expectations

Wall Street Expectations

Analysts expect a loss of $0.48 per share this quarter, with no revenue anticipated. Investors will be closely watching for any signs of progress in the company's drug development efforts.

Bull Case

If Enliven can exceed EPS expectations and provide positive updates on its pipeline, it could boost investor confidence and lead to a significant stock rally.

Bear Case

Conversely, if the company fails to meet EPS expectations or provides no clear path to future revenue, it may face further stock declines.

Key Metrics to Watch

EPS

-0.48

Earnings per share (EPS) is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

Revenue

Although no revenue is expected this quarter, any updates on future revenue streams or partnerships will be critical for investor confidence.

Expectations

Two Questions That Matter

The print will turn on these two things.

Will the EPS come in better than the consensus estimate of -0.48?

A better-than-expected EPS could signal operational improvements and boost investor sentiment.

What updates can management provide on the drug development pipeline?

Investors are keen to understand the potential for future revenue generation from ongoing projects.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street is overly pessimistic about Enliven's ability to manage costs effectively, given its recent operational improvements that may not be fully reflected in the consensus EPS estimate.

Supporting Evidence

The company has a history of beating EPS expectations, with a 75% beat rate over the last eight quarters.

Options pricing indicates a significant expected move, suggesting that investors are bracing for potential positive news.

Recent operational efficiencies may not be fully appreciated by analysts, leading to an underestimation of potential EPS improvements.

Key Risk

If the EPS comes in better than -0.44, it could challenge the current negative sentiment and lead to a reassessment of the company's outlook.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

This quarter's performance is critical as it reflects the company's ability to manage costs and progress its drug development amidst a challenging environment.

Bull Confirmed If

An EPS of -0.44 or better, along with positive commentary on the drug pipeline, would confirm the bull case.

Bear Confirmed If

An EPS worse than -0.52, coupled with no updates on revenue-generating projects, would confirm the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±39.04%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant move, suggesting that investors expect volatility around the earnings report.

Options are pricing ±39.0% while ELVN has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

45.5%

Calls (3K)P/C Ratio: 0.99Puts (39K)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Enliven beats EPS expectations, history suggests the stock could see a modest increase, confirming that operational improvements are underway.

In-Line / Cautious

If results are in line with expectations, the stock may remain stable, but cautious commentary could lead to a slight decline.

Miss

If the company misses EPS estimates, history suggests a potential decline of around 1.62%, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on the drug development pipeline and timelines for upcoming trials.
2Details on cost management strategies and their impact on future earnings.
3Insights into potential partnerships or collaborations that could drive revenue.
4Management's outlook on market conditions and how they affect the business.
5Any commentary on regulatory approvals or setbacks that could impact product launches.